Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons - Quiz - MDSpire

Evaluating the Benefits and Drawbacks of Momelotinib for Treatment-Naïve Myelofibrosis Patients

By
Naseema Gangat
Ayalew Tefferi
May 7, 2025

Blood Cancer Journal

Share

Original Source(s)

Blood Cancer Journal

Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons

by Naseema Gangat, Ayalew Tefferi
May 7, 2025

Related Content

Jama Network Open

Pediatric Reference and Optimal Curves for Hemoglobin

by Vid Bijelić, Franco Momoli, Mira Liebman, Beth K. Potter, Cornelia M. Borkhoff, Catherine S. Birken, Jonathon L. Maguire, Patricia C. Parkin, Jemila S. Hamid
June 29, 2026

Surgical Endoscopy

Surgical repair of paraesophageal hernia resolves unexplained iron deficiency anemia in the vast majority of patients: a propensity-matched multicenter study

Blood Cancer Journal

Triple-negative primary myelofibrosis: a comparative analysis of phenotype, genotype, and outcome